ER-100: The First Human Test of Cellular Reprogramming

The room, as National Geographic documented it, was an ordinary examining room in Glendale, California, this past April. An ophthalmologist disinfected a man's left eye with iodine, numbed it with lidocaine, and injected a small amount of a substance called ER-100. The patient was in his early seventies. He had lived with advanced glaucoma for decades, undergone multiple surgeries to slow it, and by then could see roughly half of what was in front of him. Someone drove him to the appointment. What went into his eye had never before been injected into a human: a preparation carrying the genetic instructions for three proteins that, in the mouse studies behind it, had reset old or damaged cells to a younger state.

The substance comes from a line of work built by Harvard geneticist David Sinclair and his former graduate student Yuancheng Ryan Lu, and licensed to Life Biosciences, the company running the trial. The eye was chosen partly for strategic reasons: it is an enclosed, immune-privileged space, and regulators prefer first-in-human experiments they can contain. Glaucoma, which destroys the optic nerve, gave the researchers a defined target. But the ambition attached to ER-100 is much larger than one eye disease. The hope is that reprogramming cells back toward a youthful state could eventually reverse damage — and perhaps aspects of aging itself — anywhere in the body.

So it is worth being precise about what just happened and what did not. A Phase 1 trial has begun. Its registered purpose is to answer one question: is ER-100 safe? According to the ClinicalTrials.gov record (NCT07290244), the study plans to enroll 18 people with glaucoma or a related optic-nerve condition called NAION, and follow them for years. No person has been shown to be rejuvenated by this or any reprogramming therapy. Every efficacy claim attached to ER-100 rests, today, on experiments in mice and in cells. That evidence is genuinely remarkable — and it is still animal evidence.

The evidence that got the needle to Glendale

The scientific path here runs through a series of verified landmarks. In 1961 Leonard Hayflick and Paul Moorhead showed that normal human cells in culture divide only a limited number of times before stopping — aging, it turned out, lives inside cells themselves. In 1993 Cynthia Kenyon's team at UCSF found that a single mutation in the worm gene daf-2 could more than double the animal's lifespan, proof that aging is genetically adjustable. In 2005, Stanford researchers joined the circulations of old and young mice and showed that something in young blood restored the regenerative capacity of aged muscle and liver cells. Aging, that experiment said, is not a one-way street; it responds to the cellular environment.

The decisive break came in 2006, when Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University showed that just four transcription factors — Oct3/4, Sox2, c-Myc and Klf4 — could return a mature mouse cell to an embryonic-like stem-cell state. The work won Yamanaka a Nobel Prize in 2012. It also carried a warning inside its own abstract: transplanted into mice, the reprogrammed cells formed tumors. Winding a cell all the way back erases its identity, and identity-loss plus growth is close to the definition of cancer.

The next move was to wind the clock only partway back. In 2016, Juan Carlos Izpisua Belmonte's group at the Salk Institute reported that short, cyclic pulses of the four factors — partial reprogramming — ameliorated cellular and physiological hallmarks of aging and extended lifespan in mice engineered to age prematurely, and improved recovery from metabolic disease and muscle injury in older normal mice. Then, in 2020, Lu, Sinclair and colleagues published the study ER-100 directly descends from. Using three of the four factors (Oct4, Sox2, Klf4 — the cancer-linked c-Myc left out) in mouse retinal ganglion cells, they restored youthful DNA-methylation patterns, promoted optic-nerve axon regeneration after injury, and reversed vision loss in a glaucoma model and in aged mice. The benefit depended on the DNA-demethylating enzymes TET1 and TET2 — evidence that the cells were not just acting younger but had measurably reset part of their epigenetic program. A 2023 follow-up from the same lab argued, in mice, that the loss of epigenetic information is itself a reversible cause of aging.

What ER-100 is — and what this trial can actually show

ER-100 packages the instructions for those same three factors with a viral delivery system that carries them into target cells. The theory is that the patient's own optic-nerve cells can be guided to clear accumulated epigenetic noise — the chemical marks that drift with age and exposure — and re-express a younger, healthier program while keeping their identity as nerve cells.

What the trial is built to measure is harm, not benefit. A first phase exists to find out whether a single injection does damage — inflammation, abnormal growth, anything worse than the disease. If the Glendale patient's vision improves, that will be an encouraging signal in one person without a control group, not evidence of efficacy. National Geographic reports that Sinclair's lab has also seen success in primates; those data have not been published, so the peer-reviewed record in any species beyond mice does not yet exist. The honest summary: a strong, replicated mouse result, a plausible mechanism, an unpublished primate claim, and one human safety trial that will take years to read out.

The complication: reprogramming and cancer are the same door

The central risk has been visible since Yamanaka's original paper. The same process that makes an old cell behave young — regained capacity to divide and repair — is, uncontrolled, what a tumor does. Push the factors too far or too long and cells lose their identity; push them in the wrong place and neighboring cells can be swept along. Johnny Kim, a regeneration researcher at the German biopharmaceutical institute TRON, told Nature earlier this year that spillover from an attempt to reprogram a large organ like the heart could be enough to transform cells into cancer. Every serious group in the field, including Sinclair's, spends most of its effort on dose control — which is why ER-100 drops c-Myc and why the first human test is confined to the eye.

There are quieter caveats too. The 2016 lifespan result came from mice with a premature-aging mutation, not normal aging. Mouse lifespans double on interventions that later do little for people. A 2024 review in Aging Cell, co-authored by Belmonte collaborator Alejandro Ocampo, describes partial reprogramming as a promising strategy while cataloguing its unresolved limitations — and notes, dryly, the field's strong commercial interests. Those interests are substantial: Google's Calico launched in 2013; Altos Labs, where Belmonte is founding scientist, started in 2022 with a reported three billion dollars; Coinbase's Brian Armstrong co-founded NewLimit; OpenAI's Sam Altman backs Retro Biosciences. Sinclair himself is an equity holder in Life Biosciences companies, as his papers' conflict-of-interest statements disclose, and his public timeline — medicines reversing aspects of aging within twenty years — is far more aggressive than Belmonte's own guess that no hallmark of aging will be reversible in his lifetime. Private funding also means much of the current data is not public.

What this means for a reader today

Practically: nothing yet. No reprogramming therapy is approved, available, or bookable, and any clinic or product already selling “Yamanaka factor” treatments, creams or facials is selling marketing, not medicine — a topical product cannot deliver gene therapy into your cells. For anyone with glaucoma or NAION, the trial registry lists the ER-100 study as recruiting, which is the legitimate door into this science; participation decisions belong with the treating physician. For everyone else, the reasonable posture is the one the evidence supports: watch the safety readout, discount the countdown clocks, and remember that the most consequential longevity interventions with human evidence behind them remain the unglamorous ones.

In Glendale, the first patient went home the same day, driven by someone else, into a follow-up schedule that will outlast most news cycles. Whether that injection becomes a footnote or a first page depends on data that does not exist yet — which is exactly what a Phase 1 trial is for. Educational, not medical advice.